What Could Come After CAR-T? Cue Is Betting On Selective Biologics
Executive Summary
Emerging Company Profile: Cue Biopharma, a young biotech formed on the basis of research from the Albert Einstein College of Medicine, is developing biologics engineered to selectively modulate disease-relevant T-cells to treat cancer – technology it has called the "next wave" in cancer immunotherapy.
You may also be interested in...
Cue Biopharma Brings Autoimmune Back To The Fore With Ono Deal
Deal Snapshot: Cue’s pipeline is heavy on oncology, but it partnered with Merck on autoimmune in 2017 and while that work has shifted to cancer, the Ono partnership puts the focus back on autoimmune disease.
IPO Update: Seven In January As Big Returns, Solid's Slip-Up Contribute To Bubble Concerns
Seven biopharma IPOs launched in the US in January with an average return of 52.8%. The most recent was Sol-Gel's on Jan. 31, but the largest was a $128m offering by ARMO. Solid had the most controversial IPO, but it still gave investors a 70.7% return, contributing to the question: Is biotech in a bubble?
IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose
With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?